Tiziana Life Sciences is trading 6.5% up today at $1.31 amid light, stock-specific news flow and potential trading volatility.
- The company recently announced on June 25, 2026, that the final patient was successfully dosed in its Phase 2 INFORM-MS trial.
- Top-line data from the trial is currently expected to be released in late Q3 or early Q4 2026.
- No new press releases or major analyst actions have emerged today, suggesting the current price action may reflect market dynamics rather than a new fundamental catalyst.